Development & Preliminary Clinical Validation Blue Light Phototherapy Systems for T-Cell
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.
研究概览
简要总结
This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's aged 18-89 at time of enrollment
- •Previous diagnosis of psoriasis vulgaris or Grover's disease
排除标准
- •All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
- •Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
- •Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
- •topical steroids
- •calcineurin inhibitors
- •methotrexate
- •retinoids
- •biologic agents
- •Unable to schedule phototherapy sessions
- •We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
研究组 & 干预措施
Adult treatment arm
Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
干预措施: Blue light phototherapy (Device)
结局指标
主要结局
Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.
时间窗: Time Frame: 5 weeks
The DLQI is a questionnaire with 10 questions. The maximum score is 30 and minimum is 0. The higher the score, the more quality of life is impaired.
Efficacy of Blue Light Therapy for Patients With Grover's Disease
时间窗: Time Frame: 5 weeks
Demonstrate preliminary skin efficacy as measured by lesion count
次要结局
未报告次要终点
研究者
Shuai (Steve) Xu
Principal Investigator
Northwestern University